Halgreen H, Pedersen N T, Worning H
Scand J Gastroenterol. 1986 Jan;21(1):104-8. doi: 10.3109/00365528609034631.
The symptomatic effect of pancreatic enzyme substitution therapy was examined in a 4-week double-blind crossover study. Twenty patients, 11 with and 9 without steatorrhoea, were examined. Pancreatic steatorrhoea was reduced from a median of 24 g/day to 10 g/day by the enzyme therapy (P less than 0.01). No significant pain reduction was found in either of the two groups, although there was a tendency to reduction in pain and analgetic consumption in the patients with steatorrhoea when treated with pancreatic enzymes. It is concluded that pancreatic steatorrhoea is still the only indication for pancreatic enzyme therapy.
在一项为期4周的双盲交叉研究中,对胰酶替代疗法的症状性效果进行了检查。研究了20名患者,其中11名有脂肪泻,9名无脂肪泻。通过酶疗法,胰腺性脂肪泻从每日中位数24克降至10克(P<0.01)。两组均未发现疼痛有显著减轻,尽管脂肪泻患者在接受胰酶治疗时疼痛有减轻趋势且镇痛药用量减少。结论是,胰腺性脂肪泻仍然是胰酶治疗的唯一指征。